Table of Contents 3
List of Tables 6
List of Figures 8
Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9
Qiagen NV, Medical Equipment Deals By Type, 2012 to YTD 2018 10
Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11
Qiagen NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 12
Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 13
Qiagen NV, Medical Equipment, Deal Details 18
Asset Purchase 18
QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18
Venture Financing 19
ArcherDX Raises USD35 Million in Series A Financing 19
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 20
Protagen Raises USD12.5 Million in Venture Financing 22
Curetis Raises USD18 Million in Extended Series B Venture Financing 23
Exosome Diagnostics Raises US$27 Million In Series B Financing Round 25
Drug Response Dx Raises Funds Through First Round Of Venture Financing 27
Xagenic Raises US$10 Million In Series A Venture Financing 28
Partnerships 29
Qiagen Enters into Licensing Agreement with Johns Hopkins University 29
QIAGEN Enters into Licensing Agreement with Johns Hopkins University 30
Qiagen Enters into Licensing Agreement with MDxHealth 31
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 32
Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 33
Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 34
Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 35
IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 36
Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 37
Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 38
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 39
QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 40
Merck and ArcherDX Enter into Co-Development Agreement 41
QIAGEN and NeuMoDx Molecular Enter into Partnership Agreement 42
Qiagen Enters into Partnership with Freenome 43
QIAGEN Enters into Agreement with Natera 44
Biomillenia Enters into Agreement with Qiagen 45
Qiagen and Centogene Enter into Co-Marketing Agreement 46
ANGLE Enters into Co-Marketing Agreement with Qiagen 47
DiaSorin Enters into Agreement with QIAGEN 48
Qiagen Forms Joint Venture with Maccura Biotech 49
ArcherDX and HeliTec Enter into Partnership 50
Singulex Enters into Agreement with Qiagen 51
Sophia Genetics Enters into Agreement with Qiagen 52
Sophia Genetics Enters into Agreement with ArcherDx 53
SeraCare Life Sciences Enters into Agreement with ArcherDx 54
Qiagen Enters into Agreement with Genohm 55
ArcherDx Enters into Partnership with PierianDx 56
ArcherDX Enters into Co-Development Agreement with Illumina 57
CareDx to Partner with Qiagen 58
Qiagen Enters into Partnership with Therawis Diagnostics 59
CosmosID Enters into Agreement with Qiagen 60
NanoString Technologies Enters into Co-Development Agreement with HalioDx 61
Qiagen Enters into Agreement with 10X Genomics 62
Qiagen Enters into Co-Development Agreement with Array BioPharma 63
ArcherDX Enters into Co-Marketing Agreement with GenomOncology 64
Qiagen Forms Joint Venture with Biotype Diagnostics 65
Qiagen Enters into Agreement with Hitachi High-Technologies 66
Qiagen Enters into Agreement with GATC Biotech 67
Tokai Pharma Expands Agreement with Qiagen 68
Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 69
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 70
Qiagen Enters into Co-Development Agreement with Novartis 71
Qiagen Enters into Co-Development Agreement with Astellas Pharma 72
AstraZeneca Enters into Co-Development Agreement with Qiagen 73
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 74
Maverix Biomics Extends Co-Marketing Agreement With Qiagen 75
Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 76
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 77
Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 78
Clovis Oncology Enters Into Co-Development Agreement With Qiagen 79
Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 81
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 82
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 84
PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 85
Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 86
Qiagen Enters Into Co-Development Agreement With Eli Lilly 87
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 88
Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 89
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 90
Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 91
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 92
Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 93
Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 94
QIAGEN Enters Into Co-Development Agreement With Insight Genetics 95
QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 96
Inserm Transfert Enters into Licensing Agreement with HalioDx 97
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 98
Transgenomic Expands Licensing Agreement with Exiqon 99
Equity Offering 100
Exiqon Completes Private Placement Of Shares For US$2.6 Million 100
Debt Offering 101
Qiagen Raises USD400 Million in Private Placement of Notes 101
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 102
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 103
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 104
Exiqon Completes Private Placement Of Bonds For US$3 Million 105
Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 106
Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 107
Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 108
Asset Transactions 109
Cryopak Industries Acquires LaunchWorks Manufacturing Lab from ArcherDX 109
Diatherix Labs Acquires Tem-PCR Patent From Qiagen 110
Acquisition 111
QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 111
Qiagen Acquires STAT-Dx 112
Qiagen Acquires OmicSoft 113
Qiagen Acquires Exiqon for up to USD102.4 Million 114
Qiagen Acquires MO BIO Labs 116
Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 117
Qiagen Acquires CLC bio 118
Enzymatics Acquires ArcherDx, Diagnostic Technology Provider, For US$50 Million 119
Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 120
Qiagen NV - Key Competitors 121
Qiagen NV - Key Employees 122
Qiagen NV - Locations And Subsidiaries 123
Head Office 123
Other Locations & Subsidiaries 123
Joint Venture 126
Recent Developments 127
Financial Announcements 127
Jul 31, 2018: QIAGEN Reports Results for Second Quarter and First Half of 2018 127
May 02, 2018: QIAGEN Announces First Quarter 2018 Financial Results 130
Jan 31, 2018: QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase 132
Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 137
May 02, 2017: QIAGEN reports results for first quarter 2017 140
Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 142
Government and Public Interest 145
Mar 30, 2017: QIAGEN joins CANCER-ID consortium for liquid biopsy workflows 145
Product News 146
Nov 15, 2017: QIAGEN advances precision medicine by automating guidelines on cancer variants in industry-leading QIAGEN Clinical Insight software 146
Apr 03, 2017: QIAGEN's GeneReader NGS System gains further validation in oncology research applications with new independent performance review data 147
Other Significant Developments 148
Sep 27, 2018: HTG Molecular announces extension to precision diagnostic partnership PDP program three for companion diagnostic submission 148
Aug 01, 2018: QIAGEN creates collaboration with Japan's largest clinical laboratory testing company, SRL, to accelerate launch of companion diagnostics 149
Feb 07, 2018: QIAGEN and Sentieon Partner to Advance Precision Medicine With Highly Efficient Variant-Calling Software 150
Jan 08, 2018: QIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio Enhancements 151
Jan 30, 2017: QIAGEN Hereditary and Rare Disease Solution Chosen by Genomics England 152
Appendix 153
Methodology 153
About GlobalData 153
Contact Us 153
Disclaimer 153

List of Tables
Qiagen NV, Medical Equipment, Key Facts, 2017 2
Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9
Qiagen NV, Medical Equipment Deals By Type, 2012 to YTD 2018 10
Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11
Qiagen NV, Deals By Market, 2012 to YTD 2018 12
Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 13
QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18
ArcherDX Raises USD35 Million in Series A Financing 19
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 20
Protagen Raises USD12.5 Million in Venture Financing 22
Curetis Raises USD18 Million in Extended Series B Venture Financing 23
Exosome Diagnostics Raises US$27 Million In Series B Financing Round 25
Drug Response Dx Raises Funds Through First Round Of Venture Financing 27
Xagenic Raises US$10 Million In Series A Venture Financing 28
Qiagen Enters into Licensing Agreement with Johns Hopkins University 29
QIAGEN Enters into Licensing Agreement with Johns Hopkins University 30
Qiagen Enters into Licensing Agreement with MDxHealth 31
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 32
Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 33
Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 34
Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 35
IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 36
Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 37
Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 38
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 39
QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 40
Merck and ArcherDX Enter into Co-Development Agreement 41
QIAGEN and NeuMoDx Molecular Enter into Partnership Agreement 42
Qiagen Enters into Partnership with Freenome 43
QIAGEN Enters into Agreement with Natera 44
Biomillenia Enters into Agreement with Qiagen 45
Qiagen and Centogene Enter into Co-Marketing Agreement 46
ANGLE Enters into Co-Marketing Agreement with Qiagen 47
DiaSorin Enters into Agreement with QIAGEN 48
Qiagen Forms Joint Venture with Maccura Biotech 49
ArcherDX and HeliTec Enter into Partnership 50
Singulex Enters into Agreement with Qiagen 51
Sophia Genetics Enters into Agreement with Qiagen 52
Sophia Genetics Enters into Agreement with ArcherDx 53
SeraCare Life Sciences Enters into Agreement with ArcherDx 54
Qiagen Enters into Agreement with Genohm 55
ArcherDx Enters into Partnership with PierianDx 56
ArcherDX Enters into Co-Development Agreement with Illumina 57
CareDx to Partner with Qiagen 58
Qiagen Enters into Partnership with Therawis Diagnostics 59
CosmosID Enters into Agreement with Qiagen 60
NanoString Technologies Enters into Co-Development Agreement with HalioDx 61
Qiagen Enters into Agreement with 10X Genomics 62
Qiagen Enters into Co-Development Agreement with Array BioPharma 63
ArcherDX Enters into Co-Marketing Agreement with GenomOncology 64
Qiagen Forms Joint Venture with Biotype Diagnostics 65
Qiagen Enters into Agreement with Hitachi High-Technologies 66
Qiagen Enters into Agreement with GATC Biotech 67
Tokai Pharma Expands Agreement with Qiagen 68
Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 69
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 70
Qiagen Enters into Co-Development Agreement with Novartis 71
Qiagen Enters into Co-Development Agreement with Astellas Pharma 72
AstraZeneca Enters into Co-Development Agreement with Qiagen 73
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 74
Maverix Biomics Extends Co-Marketing Agreement With Qiagen 75
Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 76
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 77
Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 78
Clovis Oncology Enters Into Co-Development Agreement With Qiagen 79
Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 81
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 82
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 84
PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 85
Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 86
Qiagen Enters Into Co-Development Agreement With Eli Lilly 87
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 88
Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 89
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 90
Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 91
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 92
Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 93
Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 94
QIAGEN Enters Into Co-Development Agreement With Insight Genetics 95
QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 96
Inserm Transfert Enters into Licensing Agreement with HalioDx 97
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 98
Transgenomic Expands Licensing Agreement with Exiqon 99
Exiqon Completes Private Placement Of Shares For US$2.6 Million 100
Qiagen Raises USD400 Million in Private Placement of Notes 101
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 102
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 103
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 104
Exiqon Completes Private Placement Of Bonds For US$3 Million 105
Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 106
Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 107
Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 108
Cryopak Industries Acquires LaunchWorks Manufacturing Lab from ArcherDX 109
Diatherix Labs Acquires Tem-PCR Patent From Qiagen 110
QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 111
Qiagen Acquires STAT-Dx 112
Qiagen Acquires OmicSoft 113
Qiagen Acquires Exiqon for up to USD102.4 Million 114
Qiagen Acquires MO BIO Labs 116
Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 117
Qiagen Acquires CLC bio 118
Enzymatics Acquires ArcherDx, Diagnostic Technology Provider, For US$50 Million 119
Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 120
Qiagen NV, Key Competitors 121
Qiagen NV, Key Employees 122
Qiagen NV, Subsidiaries 123
Qiagen NV, Joint Venture 126

List of Figures
Qiagen NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9
Qiagen NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 10
Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11
Qiagen NV, Medical Equipment, Deals by Market, 2012 to YTD 2018 12